The Brazilian patent for semaglutide, the active ingredient in Ozempic, is set to expire on March 20. However, consumers hoping for a price drop in the weight loss pen may be disappointed, as there are significant regulatory and industry hurdles to overcome. These challenges include existing manufacturing processes and distribution techniques that will not be easily altered to reduce prices swiftly.